Back to Search
Start Over
Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment.
- Source :
-
International journal of nanomedicine [Int J Nanomedicine] 2024 Aug 06; Vol. 19, pp. 7983-7996. Date of Electronic Publication: 2024 Aug 06 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Introduction: Osteoporosis, characterized by dysregulation of osteoclastic bone resorption and osteoblastic bone formation, severely threatens human health during aging. However, there is still no good therapy for osteoporosis, so this direction requires our continuous attention, and there is an urgent need for new drugs to solve this problem.<br />Methods: Traditional Chinese Medicine Salvia divinorum monomer pomolic acid (PA) could effectively inhibit osteoclastogenesis and ovariectomized osteoporosis. However, its poor solubility and lack of targeting severely limits its further application. A novel bone-targeting nanomedicine (PA@TLipo) has been developed to reconstruct the osteoporotic microenvironment by encapsulating pomolic acid in alendronate-functionalized liposomes. Through a series of operations such as synthesis, purification, encapsulation, and labeling, the PA@TLipo have been prepared. Moreover, the cytotoxicity, bone targeting and anti-osteoporosis effect was verified by cell and animal experiments.<br />Results: In the aspect of targeting, the PA@TLipo can effectively aggregate on the bone tissue to reduce bone loss, and in terms of toxicity, PA@TLipo could increase the bone target ability in comparison to nontargeted liposome, thereby mitigating systemic cytotoxicity. Moreover, PA@TLipo inhibited osteoclast formation and bone resorption in vitro and reduced bone loss in ovariectomy-induced osteoporotic mice.<br />Conclusion: In this study, a novel therapeutic agent was designed and constructed to treat osteoporosis, consisting of a liposome material as the drug pocket, PA as the anti-osteoporosis drug, and ALN as the bone-targeting molecule. And our study is the first to employ a bone-targeted delivery system to deliver PA for OVX-induced bone loss, providing an innovative solution for treating osteoporosis.<br />Competing Interests: The authors declare that they have no conflicts of interest in this work.<br /> (© 2024 Xia et al.)
- Subjects :
- Animals
Female
Mice
Bone Density Conservation Agents pharmacology
Bone Density Conservation Agents chemistry
Bone Density Conservation Agents administration & dosage
Osteoclasts drug effects
RAW 264.7 Cells
Humans
Bone and Bones drug effects
Bone Resorption drug therapy
Homeostasis drug effects
Osteogenesis drug effects
Ovariectomy
Liposomes chemistry
Alendronate chemistry
Alendronate pharmacology
Alendronate administration & dosage
Osteoporosis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1178-2013
- Volume :
- 19
- Database :
- MEDLINE
- Journal :
- International journal of nanomedicine
- Publication Type :
- Academic Journal
- Accession number :
- 39135672
- Full Text :
- https://doi.org/10.2147/IJN.S462514